Helex

New York, NY · Founded 2021 · Privately Held (backing)

Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney. Helex is based in New York, NY and was founded in 2021. Its last reported valuation was $36.9 million in Oct 2025. It has raised $6.6 million.

Last reported valuation
$36.9M
Oct 2026
Priced at
—
Total raised
$6.6M
Last round
—

Who backs Helex?

7 investors
InvestorType
SOSVVenture capital
IndieBioOther
New York VenturesVenture capital
Fondation BotnarVenture capital
BlueHill Capital—
Pi Ventures—
Sagana—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Helex investors

7 investors are on record for Helex, including SOSV, IndieBio, New York Ventures and Fondation Botnar.

Free account
More of Helex with a free account
  • ·Watch Helex: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 7 firms already write checks for companies like Helex. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View